Reference is made to the stock exchange announcement by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the successful completion of a private placement and retail offering of 1,650,000 new shares at NOK 90.00 per share, and to the share lending agreement entered into between the Company, ABG Sundal Collier ASA and DNB Carnegie, a part of DNB Bank ASA (the "Managers"), Hadean and Linc AB (the "Share Lending Agreement").
On 22 September 2026, Linc AB agreed to lend 555,362 shares in the Company to the Managers under the Share Lending Agreement, to facilitate delivery-versus -payment settlement of shares allocated in Tranche 1 and the Retail Offering.
The share loan will be settled by re-delivery of an equivalent number of new shares following registration of the share capital increase with the Norwegian Register of Business Enterprises.
Before the share lending, Linc AB held 555,362 shares in the Company, corresponding to 12.40% of the shares and votes. Following the share lending, Linc AB holds 0 shares (0.00%) and a right to re-delivery of 555,362 shares, corresponding to 12.40% of the shares and votes (physically settled). The total position (shares and financial instruments) is unchanged at 12.40%.
Linc AB has been allocated 192,888 Offer Shares in the Private Placement.
Following delivery of the allocated shares, Linc AB will hold 192,888 shares, corresponding to 3.15% of the Company's 6,128,412 shares and votes following registration of the share capital increase. Following re-delivery of the lent shares, Linc AB will hold 748,250 shares, corresponding to 12.21% of the shares and votes.
This information is subject to the disclosure requirements pursuant to section 4 -2 of the Norwegian Securities Trading Act.
For further information, please contact:
Oystein Soug, Chief Executive Officer